Moderna Stock News

The vaccine maker announces that Blackstone Life Sciences has agreed to fund up to $750 million for its flu program.

Moderna said on Wednesday it has entered into an agreement with private equity firm Blackstone's life science investment platform for a funding of $750 million to develop its mRNA flu vaccines.

Moderna Inc. (MRNA) on Tuesday reported "positive interim results" from a late-stage study of what it calls the "next-generation COVID-19 vaccine."

Moderna's new shot offers the potential of a longer shelf life and is one component of its combination vaccine targeting Covid and the flu.

Moderna's ‘next generation,' Covid-19 vaccine has shown a higher immune response to the virus than the current version of the shot.

The AI-in-healthcare market is expanding in the double digits and could reach more than $148 billion by the end of the decade. Nvidia CEO Jensen Huang says AI may have the most impact in the healthcar

Moderna (MRNA) concluded the recent trading session at $104.26, signifying a +0.39% move from its prior day's close.

Wood added to one of her flagship fund's biggest holdings. The superstar investor also picked up shares of two other innovators that have posted double-digit share declines in recent years.

Now might be a great time for investors to consider investing in precision medicine stocks. For those who don't know, precision medicine is an approach to disease treatment and prevention that tailors

Investing in biopharmaceutical stocks comes with more risks than some other types of stocks.

Moderna stock rallied 9% yesterday, after it launched phase 2/phase 3 clinical trials for a messenger RNA-based vaccine for skin cancer patients that it is developing with Merck. As per an earlier stu

Many investors still see Moderna as a coronavirus stock and have questioned growth prospects. The main bull case for Moderna is that it's poised to return to growth soon.

Moderna, Inc. (MRNA) Barclays 26th Annual Global Healthcare Conference (Transcript)

Moderna (MRNA) concluded the recent trading session at $110.43, signifying a -1.38% move from its prior day's close.

Moderna (MRNA) surges amid initiation reports of a phase II/III study on Merck-partnered experimental cancer therapy to treat patients with cutaneous squamous cell carcinoma, a form of skin cancer.